Harry Palmin
2018
In 2018, Harry Palmin earned a total compensation of $429.3K as Chief Operating Officer and Chief Financial Officer at Opexa Therapeutics, a 38% decrease compared to previous year.
Compensation breakdown
| Bonus | $89,250 |
|---|---|
| Salary | $340,000 |
| Total | $429,250 |
Palmin received $340K in salary, accounting for 79% of the total pay in 2018.
Palmin also received $89.3K in bonus.
Rankings
In 2018, Harry Palmin's compensation ranked 12,346th out of 14,244 executives tracked by ExecPay. In other words, Palmin earned more than 13.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,346 out of 14,244 | 13th |
Division Manufacturing | 4,993 out of 5,759 | 13th |
Major group Chemicals And Allied Products | 1,885 out of 2,122 | 11th |
Industry group Drugs | 1,613 out of 1,811 | 11th |
Industry Pharmaceutical Preparations | 1,236 out of 1,385 | 11th |
Source: SEC filing on April 12, 2019.
Palmin's colleagues
We found two more compensation records of executives who worked with Harry Palmin at Opexa Therapeutics in 2018.
News
Opexa Therapeutics CEO Chris Schelling's 2022 pay jumps 51% to $834K
April 14, 2023
Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
April 15, 2022
Opexa Therapeutics CEO Chris Schelling's 2020 pay falls 54% to $676K
April 16, 2021
Opexa Therapeutics CEO Chris Schelling's 2019 pay jumps 167% to $1.5M
October 14, 2020
Opexa Therapeutics CEO Chris Schelling's 2018 pay slips 6% to $550K
April 12, 2019